CHARLOTTESVILLE, VA, APRIL 22, 2026 — RIVANNA®, developer of AI-enabled clinical decision-support solutions, announced that it has expanded its clinical studies evaluating Accuro® XV, the company’s musculoskeletal imaging system, from two to eight sites nationwide. This expansion follows execution of a funding option by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
The study will support development of the first-ever automated fracture detection algorithm derived from volumetric ultrasound imaging. RIVANNA’s computer-aided detection (CADe/x) technology will be trained on extensive upper and lower extremity injury 3D imaging datasets collected across eight clinical sites — a foundational capability unprecedented in musculoskeletal imaging. The study will also conclude validation and training of BoneEnhance®, an image segmentation module that enhances bone visualization and represents an incremental step toward the company’s full diagnostic platform.
Renowned principal investigators at eight study sites are participating in the nationwide study: Denver Health, including Denver Health’s Emergency Department, and the Denver Health Winter Park Medical Center locations (Matthew Riscinti, MD); Texas Tech Health El Paso (Edward Michelson, MD); University of California, San Francisco (Aaron Kornblith, MD, MS); University of Utah (Christopher Kelly, MD); UVA Health (Christopher Thom, MD, RDMS); UT Southwestern Medical Center (Philip Jarrett, MD, MBA); Virginia Commonwealth University (Jordan Tozer, MD, MS, FAEMUS); and Yale University (Cristiana Baloescu, MD, MPH).